Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERMES: ziltivekimab versus placebo in heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
MOH_2023-04-13_012523Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in heart failure (HF), heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing Ziltivekimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Cardiovascular death and heart failure events. Started Dec 2022; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
heart failure (HF)heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on MOH_2023-04-13_012523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-13_012523.